BIOGY
Price
$9.50
Change
-$0.28 (-2.86%)
Updated
Aug 21 closing price
Capitalization
1.11B
SCYX
Price
$0.92
Change
+$0.03 (+3.37%)
Updated
Sep 8, 04:58 PM (EDT)
Capitalization
38.57M
57 days until earnings call
Interact to see
Advertisement

BIOGY vs SCYX

Header iconBIOGY vs SCYX Comparison
Open Charts BIOGY vs SCYXBanner chart's image
Biogaia AB
Price$9.50
Change-$0.28 (-2.86%)
Volume$1K
Capitalization1.11B
SCYNEXIS
Price$0.92
Change+$0.03 (+3.37%)
Volume$591
Capitalization38.57M
BIOGY vs SCYX Comparison Chart in %
Loading...
BIOGY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIOGY vs. SCYX commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOGY is a Hold and SCYX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (BIOGY: $9.50 vs. SCYX: $0.89)
Brand notoriety: BIOGY and SCYX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOGY: 89% vs. SCYX: 109%
Market capitalization -- BIOGY: $1.11B vs. SCYX: $38.57M
BIOGY [@Pharmaceuticals: Generic] is valued at $1.11B. SCYX’s [@Pharmaceuticals: Generic] market capitalization is $38.57M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.25B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOGY’s FA Score shows that 1 FA rating(s) are green whileSCYX’s FA Score has 0 green FA rating(s).

  • BIOGY’s FA Score: 1 green, 4 red.
  • SCYX’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOGY is a better buy in the long-term than SCYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOGY’s TA Score shows that 5 TA indicator(s) are bullish while SCYX’s TA Score has 6 bullish TA indicator(s).

  • BIOGY’s TA Score: 5 bullish, 2 bearish.
  • SCYX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, BIOGY is a better buy in the short-term than SCYX.

Price Growth

BIOGY (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was +7.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.30%. For the same industry, the average monthly price growth was +9.43%, and the average quarterly price growth was +86.94%.

Reported Earning Dates

SCYX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.30% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOGY($1.11B) has a higher market cap than SCYX($38.6M). BIOGY has higher P/E ratio than SCYX: BIOGY (31.65) vs SCYX (0.91). BIOGY YTD gains are higher at: 1.657 vs. SCYX (-26.446). BIOGY has higher annual earnings (EBITDA): 393M vs. SCYX (-19.29M). BIOGY has more cash in the bank: 622M vs. SCYX (44.8M). BIOGY has higher revenues than SCYX: BIOGY (1.44B) vs SCYX (3.26M).
BIOGYSCYXBIOGY / SCYX
Capitalization1.11B38.6M2,883%
EBITDA393M-19.29M-2,037%
Gain YTD1.657-26.446-6%
P/E Ratio31.650.913,496%
Revenue1.44B3.26M44,212%
Total Cash622M44.8M1,388%
Total DebtN/A2.39M-
FUNDAMENTALS RATINGS
BIOGY vs SCYX: Fundamental Ratings
BIOGY
SCYX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
45
Fair valued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
4397
PRICE GROWTH RATING
1..100
6055
P/E GROWTH RATING
1..100
4198
SEASONALITY SCORE
1..100
5021

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOGY's Valuation (8) in the null industry is somewhat better than the same rating for SCYX (45) in the Pharmaceuticals Other industry. This means that BIOGY’s stock grew somewhat faster than SCYX’s over the last 12 months.

BIOGY's Profit vs Risk Rating (86) in the null industry is in the same range as SCYX (100) in the Pharmaceuticals Other industry. This means that BIOGY’s stock grew similarly to SCYX’s over the last 12 months.

BIOGY's SMR Rating (43) in the null industry is somewhat better than the same rating for SCYX (97) in the Pharmaceuticals Other industry. This means that BIOGY’s stock grew somewhat faster than SCYX’s over the last 12 months.

SCYX's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as BIOGY (60) in the null industry. This means that SCYX’s stock grew similarly to BIOGY’s over the last 12 months.

BIOGY's P/E Growth Rating (41) in the null industry is somewhat better than the same rating for SCYX (98) in the Pharmaceuticals Other industry. This means that BIOGY’s stock grew somewhat faster than SCYX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOGYSCYX
RSI
ODDS (%)
Bullish Trend 4 days ago
47%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
33%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
34%
Bullish Trend 4 days ago
74%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
36%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
25%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
55%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
BIOGY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSLIX44.240.24
+0.55%
Hartford Small Cap Growth I
HRLAX9.550.03
+0.32%
Hartford Real Asset A
MKLOX20.200.06
+0.30%
BlackRock Global Allocation K
PIGRX16.900.03
+0.18%
Putnam International Value C
MSFAX35.36-0.17
-0.48%
Morgan Stanley Inst Global Franchise I

BIOGY and

Correlation & Price change

A.I.dvisor tells us that BIOGY and SCYX have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOGY and SCYX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOGY
1D Price
Change %
BIOGY100%
N/A
SCYX - BIOGY
21%
Poorly correlated
+2.43%
CANN - BIOGY
9%
Poorly correlated
-8.42%
BKUH - BIOGY
1%
Poorly correlated
N/A
BIOYF - BIOGY
1%
Poorly correlated
-1.39%
BOIRF - BIOGY
0%
Poorly correlated
N/A
More

SCYX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCYX has been loosely correlated with AKAN. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SCYX jumps, then AKAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+2.43%
AKAN - SCYX
35%
Loosely correlated
-2.54%
ELAN - SCYX
31%
Poorly correlated
+5.50%
AQST - SCYX
30%
Poorly correlated
+7.11%
SIGA - SCYX
28%
Poorly correlated
-0.82%
CRDL - SCYX
26%
Poorly correlated
-1.80%
More